| Q60683249 | Abordaje integral de la comorbilidad del paciente con psoriasis |
| Q37145684 | Cardiometabolic risk in psoriasis: differential effects of biologic agents |
| Q33870985 | Cytokine-producing dendritic cells in the pathogenesis of inflammatory skin diseases |
| Q38749538 | Effectiveness of Lipid-Lowering Statin Therapy in Patients With and Without Psoriasis |
| Q61808723 | Efficacy of Adding Oral Simvastatin to Topical Therapy for Treatment of Psoriasis: The Vietnamese Experience |
| Q37592632 | Efficacy of adding topical simvastatin to topical calcipotriol on improvement of cutaneous plaque psoriasis |
| Q33848992 | Hypercholesterolemia and risk of incident psoriasis and psoriatic arthritis in US women |
| Q64946734 | Linking CD1-Restricted T Cells With Autoimmunity and Dyslipidemia: Lipid Levels Matter. |
| Q37779736 | Lipid disturbances in psoriasis: an update. |
| Q28535430 | Novel factors in the pathogenesis of psoriasis and potential drug candidates are found with systems biology approach |
| Q34107573 | Pathogenic Mechanisms Shared between Psoriasis and Cardiovascular Disease |
| Q35045850 | Psoriasis and Metabolic Syndrome--scientific evidence and therapeutic implications |
| Q34418506 | Psoriasis and comorbidities: links and risks |
| Q21135505 | Psoriasis carries an increased risk of venous thromboembolism: a Danish nationwide cohort study |
| Q89687364 | The effect of statins on psoriasis severity: a meta-analysis of randomized clinical trials |
| Q36500064 | Transcriptome profiling unveils the role of cholesterol in IL-17A signaling in psoriasis |
| Q81817286 | [Severe psoriasis: beyond the skin, what are the risks of not treating the disease?] |